GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SMO Clinplus Co Ltd (SZSE:301257) » Definitions » EV-to-Revenue

SMO Clinplus Co (SZSE:301257) EV-to-Revenue : 1.97 (As of Jun. 06, 2024)


View and export this data going back to 2022. Start your Free Trial

What is SMO Clinplus Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, SMO Clinplus Co's enterprise value is ¥1,553.5 Mil. SMO Clinplus Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥787.4 Mil. Therefore, SMO Clinplus Co's EV-to-Revenue for today is 1.97.

The historical rank and industry rank for SMO Clinplus Co's EV-to-Revenue or its related term are showing as below:

SZSE:301257' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.91   Med: 5.61   Max: 9.52
Current: 1.97

During the past 7 years, the highest EV-to-Revenue of SMO Clinplus Co was 9.52. The lowest was 1.91. And the median was 5.61.

SZSE:301257's EV-to-Revenue is ranked better than
65% of 220 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.085 vs SZSE:301257: 1.97

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-06), SMO Clinplus Co's stock price is ¥29.32. SMO Clinplus Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥10.05. Therefore, SMO Clinplus Co's PS Ratio for today is 2.92.


SMO Clinplus Co EV-to-Revenue Historical Data

The historical data trend for SMO Clinplus Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMO Clinplus Co EV-to-Revenue Chart

SMO Clinplus Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial - - - 3.60 3.92

SMO Clinplus Co Quarterly Data
Dec17 Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.37 3.72 4.46 3.92 2.70

Competitive Comparison of SMO Clinplus Co's EV-to-Revenue

For the Diagnostics & Research subindustry, SMO Clinplus Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SMO Clinplus Co's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SMO Clinplus Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where SMO Clinplus Co's EV-to-Revenue falls into.



SMO Clinplus Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

SMO Clinplus Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1553.451/787.423
=1.97

SMO Clinplus Co's current Enterprise Value is ¥1,553.5 Mil.
SMO Clinplus Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥787.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SMO Clinplus Co  (SZSE:301257) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

SMO Clinplus Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=29.32/10.047
=2.92

SMO Clinplus Co's share price for today is ¥29.32.
SMO Clinplus Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥10.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SMO Clinplus Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of SMO Clinplus Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SMO Clinplus Co (SZSE:301257) Business Description

Traded in Other Exchanges
N/A
Address
No. 105 Sinan Road, Room 108, Building 1, Huangpu District, Shanghai, CHN, 200001
SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.
Executives
Lai Chun Bao Director
Ma Lin Director

SMO Clinplus Co (SZSE:301257) Headlines

No Headlines